Acceleron In Advanced $11B Buyout Talks: Bloomberg

Frothy rumors about possible M&A discussions at Acceleron Pharma Inc XLRN were capped with a Bloomberg report asserting that the Company is potentially in advanced talks for an $11 billion buyout deal.
Acceleron stock opened at $136.6 on 20 September and closed at $167.6 on 24 September, almost a jump of 22% during the period.
According to people familiar with the matter, Acceleron could be acquired by a large pharmaceutical company for about $180 a share in cash, Bloomberg reported. However, Bloomberg was unable to identify any bidders in the deal.
Bristol Myers Squibb & Co BMY is one likely bidder, with an 11.5% stake in Acceleron.
Bloomberg added a lineup of acquisitive players, including Sanofi SA SNY, Pfizer Inc PFE, Amgen Inc AMGN, Merck & Co Inc MRK, Gilead Sciences Inc GILD and Roche Holdings AG RHHBY.
Acceleron has gained ground with their PAH drug sotatercept, fronting positive data while their pivotal program is underway.
Related: Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients.
The Company is executing its Phase 3 sotatercept development plan for pulmonary arterial hypertension (PAH).
It is also expanding the development of sotatercept into Group 2 pulmonary hypertension, with the CADENCE Phase 2 trial expected to initiate this year.
Price Action: XLRN stock closed at $167.65 on Friday.